Category - Developments

Developments

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF) has announced the completion of patient enrollment in a pivotal clinical study evaluating its next-generation Perimeter B-Series OCT system, which combines proprietary...

October 3, 2024

Developments

Valerio acquires oncology biotech, Emglev

Valerio Therapeutics (Euronext Paris:ALVIO) has announced the acquisition of closely-held Emglev Therapeutics, a single-domain antibody-based therapeutic company and spinoff of Institut Curie, a leading cancer center in...

September 30, 2024

Developments

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that it has enrolled the last patient in its ongoing Phase IIb study of Pirepemat for Parkingson’s disease. The company also reports that a reduction in falls has...

September 30, 2024

Developments

Beyond Air and TrillaMed deploy LungFit PH into U.S. Natal Hospital Guam NICU

Beyond Air (NASDAQ:XAIR), in partnership with TrillaMed, announced that it will provide its groundbreaking LungFit PH system to the neonatal critical care unit (NICU) at U.S. Naval Hospital Guam, enabling advanced care...

September 27, 2024

Developments

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

Pasithea Therapeutics (NASDAQ:KTTA) has announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid...

September 26, 2024

Developments

NanoViricides obtains ROFR for all antiviral drug treatments from TheraCour

NanoViricides (NYSE American:NNVC) has announced that it has signed a broad memorandum of understanding agreement granting it the right of first refusal (ROFR) for all antiviral drug developments, including trojan horse...

September 26, 2024

Developments

BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs

BioRestorative Therapies (NASDAQ:BTRX) presented advancements in its metabolic program, ThermoStem, targeting obesity and metabolic disorders, at the 21st Annual International Federation for Adipose Therapeutics and...

September 25, 2024

Developments

Japan’s MHLW approves Aurinia’s LUPKYNIS (voclosporin) for lupus nephritis

Aurinia Pharmaceuticals (NASDAQ:AUPH), has announced that Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved voclosporin, a second-generation calcineurin inhibitor (CNI), in combination with...

September 25, 2024

Developments

Acurx reports CDI antibiotic research results in collaboration with LUMC

Acurx Pharmaceuticals (NASDAQ:ACXP), announced results from its research, in collaboration with Leiden University Medical Center (LUMC), for its lead oral antibiotic candidate, ibezapolstat, to treat patients with C...

September 24, 2024

Developments

Zevra receives FDA approval for Miplyffa to treat NPC

Zevra Therapeutics (NASDAQ:ZVRA), has announced FDA approval for its Miplyffa oral capsules, used in combination with miglustat, for the treatment of Niemann-Pick disease C (NPC) in adult and pediatric patients aged two...

September 23, 2024

Category - Developments

Subscribe